Company Announcements

Results of EGM

Source: RNS
RNS Number : 3042M
Hikma Pharmaceuticals Plc
20 May 2022


Hikma Pharmaceuticals PLC

Results of 2022 Extraordinary General Meeting

LONDON, 20 May 2022  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Extraordinary General Meeting ("EGM"), held at 1 New Burlington Place, W1S 2HR, London on 20 May 2022 commenced at 10:00 am. The Proposed Special Resolution was passed.

Copies of the special resolution passed at the EGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for the resolution (the full text of the resolution is detailed in the notice of the EGM dated 25 April 2022) is set out below. The number of Ordinary Shares in issue as at
20 May 2022 was 238,253,038.  There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 225,419,805.


Votes For


Votes Against


Total Cast


1. Approve the Conversion of the Merger Reserve to a Distributable Reserve








- ENDS -



Hikma Pharmaceuticals PLC


Peter Speirs

Company Secretary


+44 20 7399 2670

Susan Ringdal

EVP, Strategic Planning and Global Affairs


+44 20 7399 2670






About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.